AbbVie and Gedeon Richter tocollaborate on for the discovery and development of novel targets for neuropsychiatric conditions

This collaboration expands upon the success of nearly two decades of partnership on central nervous system (CNS) projects, including globally launched products such as cariprazine (Vraylar / Reagila and the discovery of investigational drug candidate ABBV-932 for the treatment of bipolar depression and generalized anxiety disorder. "There remains a large unmet need for people living with neuropsychiatric disorders, making it imperative that we continue to innovate and pursue novel targets and approaches to discover and develop new therapies," said Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research, AbbVie. "We are excited to expand our longstanding and successful partnership with Richter to help address the complex needs of these patients."